SCHEMBL2125273

SCHEMBL2125273

CCC(C(=O)ON1C(=O)CCC1=O)c1ccc(N2C(=O)C=CC2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
HSP90AA1 P07900 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 2/20 0.46
CACNA1B Q00975 1/20 0.46
APBA1 Q02410 1/20 0.46
MGLL Q99685 10/20 0.43
KMT2A Q03164 4/20 0.38
FAAH O00519 3/20 0.38
MEN1 O00255 2/20 0.38
DDAH1 O94760 1/20 0.37
LMNA P02545 2/20 0.37
PKM P14618 2/20 0.36
MAPK1 P28482 1/20 0.36
GLA P06280 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA1A P35348 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7381321 0.81 GAA (0.51) ALDH1A1HTTKMT2AMEN1LMNA
SCHEMBL7379862 0.81 GAA (0.51) ALDH1A1HTTKMT2AMEN1LMNA
SCHEMBL7384133 0.81 GAA (0.51) ALDH1A1HTTKMT2AMEN1LMNA
SCHEMBL15782481 0.81 MGLL (0.48) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL18639174 0.81 MGLL (0.44) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL8372896 0.81 ALDH1A1 (0.38) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL2348816 0.78 MGLL (0.53) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL3414901 0.77 MGLL (0.54) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL19309442 0.76 MGLL (0.46) ALDH1A1HSP90AA1NPSR1TDP1HPGD
SCHEMBL11030830 0.73 HPGD (0.50) ALDH1A1HSP90AA1NPSR1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712423-B2 Methods and compositions for modifying mucous membranes ABBOTT NICHOLAS L (US) 2023-08-01 US disclosed
EP-2443144-A1 SAP VARIANTS AND THEIR USE Promedior, Inc. (US) 2012-04-25 EP disclosed
WO-2010148234-A1 SAP VARIANTS AND THEIR USE PROMEDIOR, INC. (US) 2010-12-23 WO disclosed
US-20080305038-A1 Transport of Nano-and Macromolecular Structures Into Cytoplasm and Nucleus of Cells LUDWIG-MAXIMILIANS-UNIVERSITÄT (DE) 2008-12-11 US disclosed
WO-1999059643-A2 LIPOSOMAL DELIVERY COMPLEX SDG, INC. (US) 1999-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305038-A1 Transport of Nano-and Macromolecular Structures Into Cytoplasm and Nucleus of Cells NFATC1, KPNA4, KPNA1 ALDH1A1 4161/4885HSP90AA1 2014/4885NPSR1 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.